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adiation Therapy
or Breast Cancer
uyer Beware*
onald M. Witteles, MD
tanford, California
“People can foresee the future only when it coincides with
their own wishes, and the most grossly obvious facts
can be ignored when they are unwelcome.”
—George Orwell, 1945 (1)
ew medical therapies typically follow a common trajectory.
hey are originally tested in high-risk populations, in whom
he potential benefits of the intervention are most clearly
isible, and in whom the downside of side effects is relatively
inimal compared with the upside of treating the disease.
fter a therapy has been approved, its use is expanded to
ver-increasing populations, in whom the benefit is invari-
bly smaller and the relevance of side effects is invariably
arger.
There is likely no better example to illustrate this prin-
iple than with cancer therapies, often rich in both efficacy
nd in off-target side effects. Treatment with anthracyclines
r trastuzumab is frequently an easy decision in patients
ith metastatic breast cancer; such patients will almost
ertainly die of their malignancy and the risk/benefit ratio
ften clearly favors treatment (2). This becomes a much
ore difficult question in the young patient with breast
ancer with a favorable prognosis, in whom the absolute
eduction in mortality is lower, and in whom the relevance
f long-term cardiotoxicity is higher (3).
See page 445
The principle becomes further muddled when the inter-
ention being considered is radiation therapy. The difficulty
rises from the fact that the negative downstream conse-
uences of radiation may not be apparent for decades.
ence, having a true idea of the risk/benefit ratio becomes
xceedingly difficult, and by definition, clinicians and pa-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Medicine, Stanford University School ofi
edicine, Stanford, California. Dr. Witteles has reported that he has no relationships
o disclose.ients are committed to using data reflective of therapeutic
ractices decades out-of-date.
In this issue of the Journal, Bouillon et al. (4) present
onvincing evidence that radiation therapy for breast cancer
an be associated with significant increases in long-term
ardiovascular mortality. Their study represents an impor-
ant addition to the literature, due to the long duration of
ollow-up and their focus on the contribution of radiation
herapy to the internal mammary lymph nodes.
eft- versus right-sided breast cancer. One of the more
ompelling data points has been the difference in cardiovas-
ular outcomes between women treated for left- versus
ight-sided disease. For obvious anatomical reasons, therapy
or left-sided tumors results in a significantly higher radia-
ion dose to the heart. In the current study, patients with
eft-sided breast cancer had significantly higher rates of
ardiac complications, particularly after 10 years from the
ime of radiation therapy. Even more convincing was the
act that the components of “cardiovascular deaths,” which
re most plausibly influenced by radiation (heart failure,
alvular disease, ischemic disease) were the most dramati-
ally affected, whereas no such findings were seen in other
ardiac diseases (e.g., hypertensive disease, “pulmonary
eart diseases”), which are less plausibly affected by radia-
ion. Several other studies of10 to 15 years follow-up have
ound clear evidence of excess cardiovascular risk in patients
reated for left-sided disease (5–7). Increased use of anthracyclines
nd anti-HER2 therapy over the last 10 to 20 years adds another
rinkle to the equation, as their use likely further increases the
ardiac risk (8).
adiation doses. Despite the fact that substantial im-
rovements in radiation techniques have resulted in less
adiation being delivered to the heart, doses remain sub-
tantial. Recent studies documented drops in mean dose to
he heart from 13.3 to 2.3 Gy and in mean dose to the left
nterior descending artery (LAD) from 31.8 to 7.6 Gy over
he last 3 decades (9,10). Unfortunately, it is eminently
iologically plausible that these current doses of radiation
re high enough to have long-term consequences; similar or
ower dose whole-heart irradiation from survivors of atomic
ombings and from treatment of other malignancies has
een linked with increased cardiovascular mortality (11,12).
n addition, portions of the heart and LAD continue to
eceive large doses, with part of the heart receiving 20 Gy
nd part of the LAD receiving 30 Gy in many breast
ancer patients (10).
Whether or not to irradiate the internal mammary chain
IMC) nodes has been a point of pre-existing controversy—
nd this study should give clinicians even greater pause.
lthough this nodal chain has a relatively high rate of
athologic involvement, it has been unclear that this in-
olvement affects survival (13). Cardiac radiation exposure
ith IMC irradiation is substantial, even for right-sided
odes, and the evidence that such irradiation substantiallyncreases cardiovascular events/mortality is convincing (14).
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Radiation Therapy for Breast Cancer January 25, 2011:453–4n the present study, women who received left-sided IMC
rradiation had a 2-fold increase in death from cardiovas-
ular disease, and there was a strong trend for women who
eceived right-sided IMC irradiation. Tremendous institu-
ional variation currently exists in the frequency of IMC
rradiation, with no clear standard-of-care. Results of 2 in-
ernational trials intended to “definitively” address the role
f IMC irradiation are pending, but even if favorable, will
ot reflect long-term cardiovascular risks.
Multiple strategies have been proposed that affect the
adiation dose to the heart. One trend in Canada and the
nited Kingdom has been to deliver a lower total radiation
ose to the breast over a shorter interval, but at higher doses
uring each session. Whereas breast cancer outcomes to
ate have been largely equivalent (15), it is far too early to
etermine if the long-term cardiac consequences will be less
because of the lower total dose) or more (because of the
igher per-session dose). Intensity modulated radiation
herapy focuses more of the peak radiation dose toward the
ntended field, but exposes a larger field to low-dose
adiation. Prone positioning can decrease the cardiac radi-
tion dose in some patients, but can increase it in others—as
he result is entirely dependent on each patient’s individual
natomy.
urrent status. So where do we stand in 2010? Radiation
herapy has significantly improved outcomes for breast cancer,
oth in conjunction with breast-conserving therapy and with
ost-mastectomy chest wall irradiation (5,16). Furthermore, it
s impossible to believe that the real advances in radiation
echniques over the last 3 decades have not made a difference
n acquired cardiac morbidity/mortality. However, the extent
f the impact is unknown—and impossible to know—at this
oint. Disturbingly, to the extent that we have evidence, it
oints to duration of patient follow-up having a larger effect
han the era when the trials were conducted (17). As the 2 are
nextricably linked (it is impossible to have a long duration of
ollow-up in a very recent trial), physicians are left in the
nenviable position of making crucial clinical decisions with an
ncomplete data set.
There are already changes that could be implemented
oday. A young woman with early-stage breast cancer who
as initially opted for breast-conserving therapy and radia-
ion might instead opt for mastectomy if she knew that her
natomy was such that her heart/LAD was likely to receive
substantial radiation dose. Radiation therapy clearly
hould not be thrown out with the proverbial bathwater—
ut considering the data, we must approach the issue with
yes wide open. Buyer beware.
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